A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers
In brief
MKC-NI-001 is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in healthy adult volunteers. The trial consists of a Single Ascending Dose (SAD), followed by a Multiple Ascending Dose (MAD) with a primary objective to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-201 compared to placebo in healthy adult participants.
Key facts
- Study ID
- NCT06532942
- Run by
- Mannkind Corporation
- People needed
- 40
- Starts
- 2024-05-28
- Expected to finish
- 2024-10-31
- Last updated by the study team
- 2024-08-06
Who can join
Age: 40 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Flourish Research — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.